Valuation: Sernova

Market Cap 41.54M 29.61M 25.74M 23.96M 22M 2.83B 42.18M 282M 111M 1.41B 111M 109M 4.72B P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 41.54M 29.61M 25.74M 23.96M 22M 2.83B 42.18M 282M 111M 1.41B 111M 109M 4.72B EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
86.84%
Yield 2026 *
-
Yield 2027 * -
1 month-18.52%
3 months-33.33%
6 months-31.25%
Current year-15.38%
1 week 0.11
Extreme 0.11
0.12
1 month 0.1
Extreme 0.105
0.14
3 years 0.1
Extreme 0.105
0.92
5 years 0.1
Extreme 0.105
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-45.00%-87.91% 29.61M
+2.93%-1.38%-13.79%+18.62% 125B
+4.40%+2.93%+3.64%+6.41% 13.12B
+3.67%+8.56%+93.50%+123.13% 9.83B
+1.11%+10.55%-40.93%-65.72% 4.86B
-2.28%-0.67%-3.31%+36.23% 2.61B
+4.67%+7.84%+13.25%-53.59% 1.68B
+1.24%+5.88%-24.84%-30.57% 1.68B
+0.60%+5.00%-14.81%-19.58% 1.67B
Average -0.49%+3.05%-3.59%-8.11% 20.05B
Weighted average by Cap. -4.78%-0.18%-6.29%+20.07%

Financials

2026 *2027 *
Net sales - 5M 3.56M 3.1M 2.88M 2.65M 340M 5.08M 33.99M 13.34M 169M 13.39M 13.09M 568M
Net income -12.83M -9.14M -7.95M -7.4M -6.79M -873M -13.03M -87.21M -34.23M -435M -34.34M -33.58M -1.46B -19.77M -14.09M -12.25M -11.4M -10.47M -1.35B -20.08M -134M -52.76M -670M -52.93M -51.77M -2.25B
Net Debt - -
Logo Sernova
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
-
Date Price Change
31/07/26 CAD 0.1100 -.--%
30/07/26 CAD 0.1100 -.--%
29/07/26 CAD 0.1100 -4.35%
28/07/26 CAD 0.1150 -4.17%
27/07/26 CAD 0.1200 +9.09%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise